Jun. 22 at 3:21 PM
$ABBV: AbbVie is trading higher after agreeing to buy Apogee Therapeutics for
$135.11/share in cash, valuing
$APGE at about
$10.9 bln. The deal deepens ABBV’s immunology pipeline, but investors will be watching the price tag, clinical risk, and long path to EPS accretion. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/22/abbvie-catches-apogee-fever-109b-deal-expands-immunology-and-asthma-pipeline?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link
$APOG #Abbvie
$LLY $JNJ #Apogee #biotech #pharma #Immunology #asthma #healthcare #health